Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

41.81
+0.33000.80%
Pre-market: 41.78-0.0300-0.07%08:19 EDT
Volume:11.15M
Turnover:465.26M
Market Cap:30.20B
PE:-88.96
High:42.28
Open:41.39
Low:41.08
Close:41.48
52wk High:42.50
52wk Low:13.81
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.12
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:7.14
PE(LYR):-77.43

Loading ...

Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Yesterday

Top Midday Gainers

MT Newswires Live
·
Yesterday

Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright

TIPRANKS
·
Yesterday

Roivant Sciences rises 17.6%

TIPRANKS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Movement Alert|Roivant Sciences Ltd. Rises 14.2% in Regular Trading, Core Pipeline Mosliciguat Phase 2 Study Meets Primary Endpoint

Market Focus
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

Top Premarket Gainers

MT Newswires Live
·
Sep 08

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

Dow Jones
·
Sep 08

Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 08

Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
Sep 08

Movement Alert|Roivant Sciences Ltd. Rises 28.66% in Pre-Market Trading, Core Pipeline Mosliciguat Achieves Positive Clinical Data in PH-ILD Study

Market Focus
·
Sep 08

Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD

Reuters
·
Sep 08

Roivant Sciences Ltd - Phocus Met Its Primary Endpoint

THOMSON REUTERS
·
Sep 08

Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS
·
Sep 08

Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026

Reuters
·
Sep 06